Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hyperlipoproteinemias

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 253 articles:
HTML format
Text format



Single Articles


    December 2018
  1. WAKE M, Oh A, Onishi Y, Guelfucci F, et al
    Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan.
    Atherosclerosis. 2018;282:19-28.
    PubMed     Text format     Abstract available


  2. SANTOS RD, Watts GF
    Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH.
    Atherosclerosis. 2018 Dec 22. pii: S0021-9150(18)31544.
    PubMed     Text format    


  3. VEDEL-KROGH S, Kobylecki CJ, Nordestgaard BG, Langsted A, et al
    The Christmas holidays are immediately followed by a period of hypercholesterolemia.
    Atherosclerosis. 2018;281:121-127.
    PubMed     Text format     Abstract available


  4. GUO J, Gao Y, Li X, He Y, et al
    Systematic prediction of familial hypercholesterolemia caused by low-density lipoprotein receptor missense mutations.
    Atherosclerosis. 2018;281:1-8.
    PubMed     Text format     Abstract available


  5. VUORIO A, Watts GF, Kovanen PT
    Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2018;281:25-30.
    PubMed     Text format     Abstract available


  6. LUNEGOVA OS, Mirrakhimov EM
    A familial hypercholesterolemia week in Kyrgyzstan: The joint scientific and practical symposium with the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS) and the Kyrgyz Society of Cardiology (KSC).
    Atherosclerosis. 2018 Dec 3. pii: S0021-9150(18)31511.
    PubMed     Text format    


    November 2018
  7. SORAN H, Adam S, Durrington PN
    Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' ".
    Atherosclerosis. 2018 Nov 28. pii: S0021-9150(18)31508.
    PubMed     Text format    


  8. KORDONOURI O, Lange K, Boettcher I, Christoph J, et al
    New approach for detection of LDL-hypercholesterolemia in the pediatric population: The Fr1dolin-Trial in Lower Saxony, Germany.
    Atherosclerosis. 2018;280:85-91.
    PubMed     Text format     Abstract available


  9. PIRRO M, Francisci D, Bianconi V, Schiaroli E, et al
    NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial.
    Atherosclerosis. 2018;280:51-57.
    PubMed     Text format     Abstract available


  10. SHAH SR
    Comments on "Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk".
    Atherosclerosis. 2018 Nov 13. pii: S0021-9150(18)31476.
    PubMed     Text format    


  11. HUMPHRIES SE, Cooper JA, Capps N, Durrington PN, et al
    Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.
    Atherosclerosis. 2018 Nov 12. pii: S0021-9150(18)31469.
    PubMed     Text format     Abstract available


  12. REESKAMP LF, Kastelein JJP, Moriarty PM, Duell PB, et al
    Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2018;280:109-117.
    PubMed     Text format     Abstract available


  13. LUIJTEN J, van Greevenbroek MMJ, Schaper NC, Meex SJR, et al
    Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study.
    Atherosclerosis. 2018;280:1-6.
    PubMed     Text format     Abstract available


    October 2018
  14. ALHABABI D, Zayed H
    Spectrum of mutations of familial hypercholesterolemia in the 22 Arab countries.
    Atherosclerosis. 2018;279:62-72.
    PubMed     Text format     Abstract available


  15. SHEK A, Alieva R, Kurbanov R, Hoshimov S, et al
    Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
    Atherosclerosis. 2018;277:524-529.
    PubMed     Text format     Abstract available


  16. MEHTA R, Martagon AJ, Galan Ramirez GA, Gonzalez Retana G, et al
    The development of the Mexican Familial Hypercholesterolemia (FH) National Registry.
    Atherosclerosis. 2018;277:517-523.
    PubMed     Text format     Abstract available


  17. AZRAII AB, Ramli AS, Ismail Z, Abdul-Razak S, et al
    Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training.
    Atherosclerosis. 2018;277:508-516.
    PubMed     Text format     Abstract available


  18. BOTHA TC, Pilcher GJ, Wolmarans K, Blom DJ, et al
    Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies.
    Atherosclerosis. 2018;277:502-507.
    PubMed     Text format     Abstract available


  19. HAGGER MS, Hardcastle SJ, Hu M, Kwok S, et al
    Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:493-501.
    PubMed     Text format     Abstract available


  20. RAAL FJ, Hovingh GK, Catapano AL
    Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Atherosclerosis. 2018;277:483-492.
    PubMed     Text format     Abstract available


  21. AFANASIEVA OI, Ezhov MV, Razova OA, Afanasieva MI, et al
    Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Atherosclerosis. 2018;277:477-482.
    PubMed     Text format     Abstract available


  22. PANG J, David Marais A, Blom DJ, Brice BC, et al
    Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice.
    Atherosclerosis. 2018;277:470-476.
    PubMed     Text format     Abstract available


  23. SOUTO AC, Miname MH, Fukushima J, Jannes CE, et al
    Health related quality of life in individuals at high risk for familial hypercholesterolemia undergoing genetic cascade screening in Brazil.
    Atherosclerosis. 2018;277:464-469.
    PubMed     Text format     Abstract available


  24. FUTEMA M, Bourbon M, Williams M, Humphries SE, et al
    Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.
    Atherosclerosis. 2018;277:457-463.
    PubMed     Text format     Abstract available


  25. ALVES AC, Benito-Vicente A, Medeiros AM, Reeves K, et al
    Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia.
    Atherosclerosis. 2018;277:448-456.
    PubMed     Text format     Abstract available


  26. HSIUNG YC, Lin PC, Chen CS, Tung YC, et al
    Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
    Atherosclerosis. 2018;277:440-447.
    PubMed     Text format     Abstract available


  27. LOPEZ G, Bernal LM, Gelvez N, Gomez LF, et al
    Mutational analysis of the LDLR gene in a cohort of Colombian families with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:434-439.
    PubMed     Text format     Abstract available


  28. ALNOURI F, Athar M, Al-Allaf FA, Abduljaleel Z, et al
    Novel combined variants of LDLR and LDLRAP1 genes causing severe familial hypercholesterolemia.
    Atherosclerosis. 2018;277:425-433.
    PubMed     Text format     Abstract available


  29. BRUNHAM LR, Ruel I, Khoury E, Hegele RA, et al
    Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.
    Atherosclerosis. 2018;277:419-424.
    PubMed     Text format     Abstract available


  30. PETRULIONIENE Z, Gargalskaite U, Kutkiene S, Staigyte J, et al
    Establishing a national screening programme for familial hypercholesterolaemia in Lithuania.
    Atherosclerosis. 2018;277:407-412.
    PubMed     Text format     Abstract available


  31. BRETT T, Qureshi N, Gidding S, Watts GF, et al
    Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.
    Atherosclerosis. 2018;277:399-406.
    PubMed     Text format     Abstract available


  32. TRUONG TH, Kim NT, Nguyen MNT, Pang J, et al
    Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
    Atherosclerosis. 2018;277:392-398.
    PubMed     Text format     Abstract available


  33. GROSELJ U, Kovac J, Sustar U, Mlinaric M, et al
    Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review.
    Atherosclerosis. 2018;277:383-391.
    PubMed     Text format     Abstract available


  34. PAYNE J, Williams S, Maxwell D, Pariente MT, et al
    Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective.
    Atherosclerosis. 2018;277:377-382.
    PubMed     Text format     Abstract available


  35. DESCAMPS OS, Van Caenegem O, Hermans MP, Balligand JL, et al
    A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
    Atherosclerosis. 2018;277:369-376.
    PubMed     Text format     Abstract available


  36. HARADA-SHIBA M, Ako J, Arai H, Hirayama A, et al
    Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study.
    Atherosclerosis. 2018;277:362-368.
    PubMed     Text format     Abstract available


  37. VRABLIK M, Raslova K, Vohnout B, Blaha V, et al
    Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
    Atherosclerosis. 2018;277:355-361.
    PubMed     Text format     Abstract available


  38. LATKOVSKIS G, Saripo V, Gilis D, Nesterovics G, et al
    Latvian registry of familial hypercholesterolemia: The first report of three-year results.
    Atherosclerosis. 2018;277:347-354.
    PubMed     Text format     Abstract available


  39. KAYIKCIOGLU M, Tokgozoglu L, Dogan V, Ceyhan C, et al
    What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
    Atherosclerosis. 2018;277:341-346.
    PubMed     Text format     Abstract available


  40. BELIARD S, Boccara F, Cariou B, Carrie A, et al
    High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Atherosclerosis. 2018;277:334-340.
    PubMed     Text format     Abstract available


  41. VAN DELDEN XM, Huijgen R, Wolmarans KH, Brice BC, et al
    LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    Atherosclerosis. 2018;277:327-333.
    PubMed     Text format     Abstract available


  42. VOHNOUT B, Fabryova L, Klabnik A, Kadurova M, et al
    Treatment pattern of familial hypercholesterolemia in Slovakia: Targets, treatment and obstacles in common practice.
    Atherosclerosis. 2018;277:323-326.
    PubMed     Text format     Abstract available


  43. SCHMIDT N, Dressel A, Grammer TB, Gouni-Berthold I, et al
    Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
    Atherosclerosis. 2018;277:314-322.
    PubMed     Text format     Abstract available


  44. RIZOS CV, Elisaf MS, Skoumas I, Tziomalos K, et al
    Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Atherosclerosis. 2018;277:308-313.
    PubMed     Text format     Abstract available


  45. DUMITRESCU A, Mosteoru S, Vinereanu D, Dan GA, et al
    Preliminary data of familial hypercholesterolemia (FH) patients in Romania.
    Atherosclerosis. 2018;277:304-307.
    PubMed     Text format     Abstract available


  46. LALIC K, Rajkovic N, Popovic L, Lukac SS, et al
    The effects of 3-year statin therapy and the achievement of LDL cholesterol target values in familial hypercholesterolemia patients: An experience from Serbia.
    Atherosclerosis. 2018;277:298-303.
    PubMed     Text format     Abstract available


  47. VALLEJO-VAZ AJ, Ray KK
    Epidemiology of familial hypercholesterolaemia: Community and clinical.
    Atherosclerosis. 2018;277:289-297.
    PubMed     Text format     Abstract available


  48. MISEREZ AR, Martin FJ, Spirk D
    DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
    Atherosclerosis. 2018;277:282-288.
    PubMed     Text format     Abstract available


  49. POJSKIC L, Pojskic B
    Familial hypercholesterolemia screening program in Bosnia and Herzegovina and cardiovascular morbidity.
    Atherosclerosis. 2018;277:278-281.
    PubMed     Text format     Abstract available


  50. HARADA PH, Miname MH, Bensenor IM, Santos RD, et al
    Familial hypercholesterolemia prevalence in an admixed racial society: Sex and race matter. The ELSA-Brasil.
    Atherosclerosis. 2018;277:273-277.
    PubMed     Text format     Abstract available


  51. KUTKIENE S, Petrulioniene Z, Laucevicius A, Cerkauskiene R, et al
    Lipid profile evaluation and severe hypercholesterolaemia screening in the middle-aged population according to nationwide primary prevention programme in Lithuania.
    Atherosclerosis. 2018;277:267-272.
    PubMed     Text format     Abstract available


  52. PARAGH G, Harangi M, Karanyi Z, Daroczy B, et al
    Identifying patients with familial hypercholesterolemia using data mining methods in the Northern Great Plain region of Hungary.
    Atherosclerosis. 2018;277:262-266.
    PubMed     Text format     Abstract available


  53. CORRAL P, Geller AS, Polisecki EY, Lopez GI, et al
    Unusual genetic variants associated with hypercholesterolemia in Argentina.
    Atherosclerosis. 2018;277:256-261.
    PubMed     Text format     Abstract available


  54. VALLEJO-VAZ AJ, De Marco M, Stevens CAT, Akram A, et al
    Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Atherosclerosis. 2018;277:234-255.
    PubMed     Text format     Abstract available


  55. RAY KK, Watts GF
    Improving the global care of familial hypercholesterolaemia: Starting the ball rolling.
    Atherosclerosis. 2018;277:230-233.
    PubMed     Text format    


  56. IBARRETXE D, Rodriguez-Borjabad C, Feliu A, Bilbao JA, et al
    Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project.
    Atherosclerosis. 2018;278:210-216.
    PubMed     Text format     Abstract available


    September 2018
  57. OUWENEEL AB, Hoekstra M, van der Wel EJ, Schaftenaar FH, et al
    Hypercholesterolemia impairs megakaryopoiesis and platelet production in scavenger receptor BI knockout mice.
    Atherosclerosis. 2018 Sep 22. pii: S0021-9150(18)31392.
    PubMed     Text format     Abstract available


  58. JUNG KJ, Koh H, Choi Y, Lee SJ, et al
    Familial hypercholesterolemia and atherosclerotic cardiovascular mortality among Korean adults with low levels of serum cholesterol.
    Atherosclerosis. 2018;278:103-109.
    PubMed     Text format     Abstract available


  59. FARNIER M, Hovingh GK, Langslet G, Dufour R, et al
    Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program.
    Atherosclerosis. 2018 Sep 1. pii: S0021-9150(18)31345.
    PubMed     Text format     Abstract available


    August 2018
  60. SORAN H, Adam S, Durrington PN
    Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Atherosclerosis. 2018;278:135-142.
    PubMed     Text format     Abstract available


  61. BELIARD S, Gallo A, Duchene E, Carrie A, et al
    Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort.
    Atherosclerosis. 2018;277:66-71.
    PubMed     Text format     Abstract available


  62. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Corrigendum to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)" [Atherosclerosis 259 (2017 Apr) 20-25].
    Atherosclerosis. 2018;275:461-462.
    PubMed     Text format    


    July 2018
  63. MARTIN SS
    Calculating LDL cholesterol in familial combined hyperlipidemia: Out with the old, in with the new?
    Atherosclerosis. 2018 Jul 27. pii: S0021-9150(18)31241.
    PubMed     Text format    


  64. CAO YX, Liu HH, Sun D, Jin JL, et al
    The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia.
    Atherosclerosis. 2018;277:7-14.
    PubMed     Text format     Abstract available


    June 2018
  65. ADEMI Z, Martin AC
    Universal screening of children for familial hypercholesterolaemia: Value for money?
    Atherosclerosis. 2018 Jun 22. pii: S0021-9150(18)31186.
    PubMed     Text format    


  66. MEHTA R, Reyes-Rodriguez E, Yaxmehen Bello-Chavolla O, Guerrero-Diaz AC, et al
    Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia.
    Atherosclerosis. 2018 Jun 21. pii: S0021-9150(18)31180.
    PubMed     Text format     Abstract available


  67. BALLANTYNE CM, Banach M, Mancini GBJ, Lepor NE, et al
    Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Atherosclerosis. 2018 Jun 12. pii: S0021-9150(18)30309.
    PubMed     Text format     Abstract available


  68. MCKAY AJ, Hogan H, Humphries SE, Marks D, et al
    Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    Atherosclerosis. 2018 Jun 4. pii: S0021-9150(18)30290.
    PubMed     Text format     Abstract available


    May 2018
  69. MULLER HH
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study.
    Atherosclerosis. 2018 May 30. pii: S0021-9150(18)30260.
    PubMed     Text format    


  70. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Reply to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis: Corrections of the report on the randomized MICA-study".
    Atherosclerosis. 2018 May 22. pii: S0021-9150(18)30261.
    PubMed     Text format    


  71. CROSLAND P, Maconachie R, Buckner S, McGuire H, et al
    Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Atherosclerosis. 2018;275:80-87.
    PubMed     Text format     Abstract available


  72. HUMPHRIES SE, Cooper JA, Seed M, Capps N, et al
    Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register.
    Atherosclerosis. 2018;274:41-46.
    PubMed     Text format     Abstract available


    April 2018
  73. WENG S, Kai J, Tranter J, Leonardi-Bee J, et al
    Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study.
    Atherosclerosis. 2018;274:54-60.
    PubMed     Text format     Abstract available


    March 2018
  74. WAKE M, Onishi Y, Guelfucci F, Oh A, et al
    Treatment patterns in hyperlipidaemia patients based on administrative claim databases in Japan.
    Atherosclerosis. 2018;272:145-152.
    PubMed     Text format     Abstract available


    February 2018
  75. ZHAO Y, Yang Y, Xing R, Cui X, et al
    Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats.
    Atherosclerosis. 2018;271:26-35.
    PubMed     Text format     Abstract available


  76. VITVEROVA B, Blazickova K, Najmanova I, Vicen M, et al
    Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta.
    Atherosclerosis. 2018;271:15-25.
    PubMed     Text format     Abstract available


  77. FOGACCI F, Cicero AFG
    Gene targeting for chylomicronemia syndrome: The brave new world.
    Atherosclerosis. 2018;269:254-255.
    PubMed     Text format    


    January 2018
  78. PELCZARSKA A, Jakubczyk M, Jakubiak-Lasocka J, Banach M, et al
    The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Atherosclerosis. 2018;270:132-138.
    PubMed     Text format     Abstract available


  79. RODRIGUEZ-BORJABAD C, Ibarretxe D, Girona J, Ferre R, et al
    Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.
    Atherosclerosis. 2018;270:117-122.
    PubMed     Text format     Abstract available


  80. KAYIKCIOGLU M, Tokgozoglu L, Yilmaz M, Kaynar L, et al
    A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
    Atherosclerosis. 2018;270:42-48.
    PubMed     Text format     Abstract available


  81. DROUIN-CHARTIER JP, Tremblay AJ, Bergeron J, Lamarche B, et al
    High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Atherosclerosis. 2018;270:26-32.
    PubMed     Text format     Abstract available


    December 2017
  82. PEK SLT, Dissanayake S, Fong JCW, Lin MX, et al
    Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
    Atherosclerosis. 2017;269:106-116.
    PubMed     Text format     Abstract available


  83. SANCHEZ-HERNANDEZ RM, Prieto-Matos P, Civeira F, Lafuente EE, et al
    Autosomal recessive hypercholesterolemia in Spain.
    Atherosclerosis. 2017;269:1-5.
    PubMed     Text format     Abstract available


    October 2017
  84. HOEKE G, Wang Y, van Dam AD, Mol IM, et al
    Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis.
    Atherosclerosis. 2017;267:116-126.
    PubMed     Text format     Abstract available


  85. AMROCK SM, Duell PB, Knickelbine T, Martin SS, et al
    Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH patient registry.
    Atherosclerosis. 2017;267:19-26.
    PubMed     Text format     Abstract available


    September 2017
  86. HOVLAND A, Mundal LJ, Igland J, Veierod MB, et al
    Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;266:69-73.
    PubMed     Text format     Abstract available


  87. CHRISTENSEN JJ, Ulven SM, Retterstol K, Narverud I, et al
    Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study.
    Atherosclerosis. 2017;266:48-57.
    PubMed     Text format     Abstract available


  88. KAWASHIRI MA, Nohara A, Higashikata T, Tada H, et al
    Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Atherosclerosis. 2017;265:225-230.
    PubMed     Text format     Abstract available


    August 2017
  89. SCHMIDT N, Schmidt B, Dressel A, Gergei I, et al
    Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study.
    Atherosclerosis. 2017;266:24-30.
    PubMed     Text format     Abstract available


  90. SPINA R, Cefalu' AB, Noto D, Ingrassia V, et al
    Identification of a novel LMF1 nonsense mutation responsible for severe hypertriglyceridemia by targeted next-generation sequencing.
    Atherosclerosis. 2017;263:e99.
    PubMed     Text format    


  91. ELLIS K, Pang J, Bell D, Burnett J, et al
    Elevated lipoprotein(a) and familial hypercholesterolaemia phenotypes in patients admitted to a coronary care unit with coronary artery disease.
    Atherosclerosis. 2017;263:e99.
    PubMed     Text format    


  92. MINICOCCI I, Pozzessere S, Prisco C, Montali A, et al
    Mutational analysis of children and adolescents with familial hypercholesterolemia ascertained by child-parent screening.
    Atherosclerosis. 2017;263:e99.
    PubMed     Text format    


  93. COUVERT P, Giral P, Boelle PY, Carreau V, et al
    Genetic testing of familial hypercholesterolemia: Monogenic form and polygenic contribution to cardiovascular risk.
    Atherosclerosis. 2017;263:e94.
    PubMed     Text format    


  94. GAUDET D, Gipe D, Hovingh K, Ahmad Z, et al
    Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, proof-of-concept study.
    Atherosclerosis. 2017;263:e9.
    PubMed     Text format    


  95. GHALEB Y, Elbitar S, El Khoury P, Rabes JP, et al
    Usefulness of the genetic risk score to identify phenocopies in families with autosomal dominant hypercholesterolemia?
    Atherosclerosis. 2017;263:e83.
    PubMed     Text format    


  96. VERBEEK R, Oldoni F, Boekholdt SM, Zwinderman A, et al
    Multilocus gene score or a metabolic risk score for severe hypertriglyceridemia and CVD risk prediction.
    Atherosclerosis. 2017;263:e83.
    PubMed     Text format    


  97. MUNDAL L, Igland J, Tell GS, Veierod M, et al
    Standardized incidence ratio of peripheral arterial disease and aortic stenosis in genotyped familial hypercholesterolemia in Norway during 2001-2009.
    Atherosclerosis. 2017;263:e78.
    PubMed     Text format    


  98. HUSEYNOV R, Kayikcioglu M, Bayraktaroglu S, Can L, et al
    The relationship between lipoprotein A and aortic calsification in patients with hypercholesterolemia.
    Atherosclerosis. 2017;263:e67.
    PubMed     Text format    


  99. BENEDEK P, Angelin B, Duvefelt K, Hong J, et al
    The use of genotyping as a first step in molecular diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e62.
    PubMed     Text format    


  100. PANG J, Abraham A, Bates TR, Bell DA, et al
    Subclinical coronary artery disease in asymptomatic patients with and without genetically confirmed familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e61-e62.
    PubMed     Text format    


  101. MEDEIROS AM, Alves AC, Bourbon M
    APOB/APOA1 ratio and APOC2 are the best biomarkers to distinguish familial hypercholesterolemia from other dyslipidaemia.
    Atherosclerosis. 2017;263:e61.
    PubMed     Text format    


  102. RYAN JD, Pang J, Watts GF, Vickery A, et al
    Using general practice electronic databases to increase the identification of familial hypercholesterolaemia in primary care.
    Atherosclerosis. 2017;263:e61.
    PubMed     Text format    


  103. RAMO J, Ripatti P, Tabassum R, Soderlund S, et al
    Mass spectrometry of circulating lipid species highlights similarity of familial hyperlipidemias and hyperlipidemias in the general population.
    Atherosclerosis. 2017;263:e61.
    PubMed     Text format    


  104. RAHMAT R, Chua YA, Ismail Z, Mohd Kasim NA, et al
    Elevated serum lipoprotein(A) concentrations in different sub-groups of clinical familial hypercholesterolaemia and their unaffected family members.
    Atherosclerosis. 2017;263:e60.
    PubMed     Text format    


  105. CHRISTENSEN JJ, Osnes L, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e58.
    PubMed     Text format    


  106. OLIYARNYK O, Markova I, Malinska H, Trnovska J, et al
    Combination of silymarin with N-3 Polyunsaturated fatty acids enhances hepatoprotective effect of silymarin in hereditary hypertriglyceridemic rats.
    Atherosclerosis. 2017;263:e44.
    PubMed     Text format    


  107. HANDE L, Thunhaug H, Enebakk T, Ludviksen JA, et al
    Addition of polyunsaturated fatty acids to statins in familial hypercholesterolemia does not affect in vitro or in vivo endothelial function.
    Atherosclerosis. 2017;263:e43.
    PubMed     Text format    


  108. GONZALEZ-ESTRADA A, Alarcon-Garcia JC, Garcia-Ocana P, Camacho-Carrasco A, et al
    Alirocumab in patients with heterozygous familial hypercholesterolemia: Clinical experience in 27 patients at a tertiary care center in Southern Spain.
    Atherosclerosis. 2017;263:e42-e43.
    PubMed     Text format    


  109. DOWNIE P, Gritzmacher L, Palmer F, Bayly G, et al
    The variable effect of PCSK9 inhibition in patients with homozygous familial hypercholesterolaemia: Evidence to support the existence of alternative cholesterol lowering pathways.
    Atherosclerosis. 2017;263:e42.
    PubMed     Text format    


  110. PEREZ-CALAHORRA S, Plana N, Ma Sanchez-Hernandez R, Marco-Benedi V, et al
    Candidates for monoclonal antibodies to PCSK9, among heterozygous familial hypercholesterolemia patients in the dyslipidemia registry of the Spanish atherosclerosis society.
    Atherosclerosis. 2017;263:e41-e42.
    PubMed     Text format    


  111. RIPATTI P, Ramo J, Soderlund S, Surakka I, et al
    Polygenic hyperlipidemia and coronary artery disease risk.
    Atherosclerosis. 2017;263:e4.
    PubMed     Text format    


  112. LAMIQUIZ MONEO I, Baila Rueda L, Bea Sanz AM, Gallego RM, et al
    ABCG5/G8 mutations in non FH genetic hypercholesterolemias.
    Atherosclerosis. 2017;263:e39-e40.
    PubMed     Text format    


  113. BIGOLIN P, Antonucci A, Marin R, Vianello D, et al
    Genetic diagnosis of familial hypercholesterolaemia: Preliminary data from the university of padua outpatient lipid clinic.
    Atherosclerosis. 2017;263:e39.
    PubMed     Text format    


  114. HUMPHRIES S, Futema M, Cooper J, Charakida M, et al
    SEnsitivity and specificity of biochemical screening for familial hypercholesterolaemia in childhood: avon longitudinal study of parents and children (ALSPAC).
    Atherosclerosis. 2017;263:e39.
    PubMed     Text format    


  115. PETROV I, Postadzhiyan A, Tokmakova M, Addison J, et al
    Management of high and very high risk patients with familial hypercholesterolemia: Results from an observational study in Bulgaria.
    Atherosclerosis. 2017;263:e38-e39.
    PubMed     Text format    


  116. BAILA-RUEDA L, Civeira F, Lamiquiz-Moneo I, Mateo-Gallego R, et al
    Familial combined hypercholesterolemia differs from other genetic hypercholesterolemias in the hepatic cholesterol production.
    Atherosclerosis. 2017;263:e38.
    PubMed     Text format    


  117. GARCIA UG, Vicente AB, Etxebarria A, Palacios L, et al
    The leucine stretch length of PCSK9 signal peptide and its role in development of autosomal dominant hypercholesterolaemia: Unravelling the activities of P.LEU23DEL and P.LEU22_LEU23DUP variants.
    Atherosclerosis. 2017;263:e37.
    PubMed     Text format    


  118. NOHARA A, Kawashiri MA, Eto Y, Fujisaki M, et al
    Common functional variant LIPA T16P affects HDL composition among patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e37-e38.
    PubMed     Text format    


  119. SIMIONESCU N, Carnuta MG, Fuior EV, Stancu CS, et al
    Targeting lipid metabolism-related genes by in vivo inhibition of MIR-486 and MIR-92A lowers plasma cholesterol levels in hyperlipidemic hamsters.
    Atherosclerosis. 2017;263:e34-e35.
    PubMed     Text format    


  120. BARALE C, Bonomo K, Noto F, Traversa M, et al
    Effects of PCSK9 inhibitors on platelet function in adults with hypercholesterolemia.
    Atherosclerosis. 2017;263:e30-e31.
    PubMed     Text format    


  121. BASSANI BORGES J, Medeiros Bastos G, Almendros Afonso TK, Da Silva Rodrigues E, et al
    Next generation sequencing in the diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e282.
    PubMed     Text format    


  122. SHCHERBAKOVA N, Ershova A, Zharikova A, Meshkov A, et al
    Genetics of familial hypercholesterolemia in patients recruited from epidemiological study.
    Atherosclerosis. 2017;263:e281.
    PubMed     Text format    


  123. RONEN D, Ibe UK, Shoshi S, Daniel S, et al
    Molecular genetics of familial hypercholesterolemia in Israel - revisited.
    Atherosclerosis. 2017;263:e279-e280.
    PubMed     Text format    


  124. DLOUHA D, Blaha M, Blaha V, Fatorova I, et al
    Analysis of circulating mirnas in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
    Atherosclerosis. 2017;263:e278.
    PubMed     Text format    


  125. ZHILINA S, Miramontes Gonzalez JP, Laso Guzman FJ
    Familial hypercholesterolemia and the diabetogenic effect of statins.
    Atherosclerosis. 2017;263:e264.
    PubMed     Text format    


  126. LIND L, Onnerhag K, Riserus U, Kvarnstrom M, et al
    Effects of free omega-3 carboxylic acids and fenofibrate on liver steatosis and serum lipoproteins in overweight patients with hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD).
    Atherosclerosis. 2017;263:e260.
    PubMed     Text format    


  127. RETTERSTOL K, Mundal L, Igland J, Seppola Tell G, et al
    Incidence of various types of atherosclerotic disease in patients with genotyped familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e26.
    PubMed     Text format    


  128. TICHY L, Pavlouskova J, Reblova K, Freiberger T, et al
    Autosomal dominant hypercholesterolemia in the czech republic - introduction of the next generation sequencing.
    Atherosclerosis. 2017;263:e26.
    PubMed     Text format    


  129. PAPAKONSTANTINOU P, Theodoraki E, Koulentaki M, Papadakis J, et al
    New-onset severe hypercholesterolemia in a patient with cholestatic liver disease. Should we treat the lipids?
    Atherosclerosis. 2017;263:e253-e254.
    PubMed     Text format    


  130. GROSELJ U, Kovac J, Klancar G, Pohleven S, et al
    Characteristics of children with familial and polygenic hypercholesterolemia referred through the national universal hypercholesterolemia screening - a preliminary report.
    Atherosclerosis. 2017;263:e25-e26.
    PubMed     Text format    


  131. SIMONELLI F, Miotti C, Filice BF, Gallo G, et al
    Plasmatic and phenotypic effects with alirocumab, a PCSK9 inhibitor, in familial hypercholesterolemia treatment (FH).
    Atherosclerosis. 2017;263:e246-e247.
    PubMed     Text format    


  132. GRAESDAL A, Dybvig A
    Lipoprotein apheresis as a treatment modality for familial combined hyperlipidemia (FCH) with non-alcoholic fatty liver disease (NAFLD) and coronary heart disease: a casuistic approach.
    Atherosclerosis. 2017;263:e243-e244.
    PubMed     Text format    


  133. VALLEJO-VAZ AJ, Roth EM, Hovingh GK, Lee LV, et al
    Predictive factors for alirocumab dose increase in patients with heterozygous familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e243.
    PubMed     Text format    


  134. UZOKOV J, Alyavi A, Alyavi B
    Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome.
    Atherosclerosis. 2017;263:e241.
    PubMed     Text format    


  135. YASUDA H, Fujiwara A, Komiya S, Haze T, et al
    Effects of rosuvastatin add-on treatment on hyperlipidemia in type 2 diabetic patients with chronic kidney disease receiving ethyl icosapentate.
    Atherosclerosis. 2017;263:e241-e242.
    PubMed     Text format    


  136. HUMPHRIES S, Pears R, Miedzybrodzka Z, Haralambos K, et al
    Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from FH services in the UK.
    Atherosclerosis. 2017;263:e24-e25.
    PubMed     Text format    


  137. GONZALEZ MOLERO I, Olveira G, Tinahones F
    Features of first patients treated with PCSK9 inhibitors in a specific lipid unit and effectiveness on lipid profile in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e239.
    PubMed     Text format    


  138. GURINA N, Loukianov M, Martsevich S, Zagrebelny A, et al
    Prescription patterns of lipid-lowering therapy in patients with cardiovascular disease and hypertriglyceridemia in real clinical practice in Russia.
    Atherosclerosis. 2017;263:e237.
    PubMed     Text format    


  139. IACOCCA M, Wang J, Dron J, Robinson J, et al
    Use of next-generation sequencing to detect copy number variations in the molecular diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e236.
    PubMed     Text format    


  140. WU X, Pang J, Peng J, Chen Y, et al
    Effectiveness of reverse cascade screening for familial hypercholesteroleamia in very high risk families in China.
    Atherosclerosis. 2017;263:e235-e236.
    PubMed     Text format    


  141. GIAMMANCO A, Spina R, Ingrassia V, Valenti V, et al
    Genotypic and phenotypic characterization of patients with autosomal dominant hypercholesterolemia in sicily.
    Atherosclerosis. 2017;263:e235.
    PubMed     Text format    


  142. BEHESHTI S, Madsen CM, Varbo A, Nordestgaard BG, et al
    2.6-fold risk of ischemic stroke in individuals with clinical familial hypercholesterolemia: The copenhagen general population study with 102,961 individuals.
    Atherosclerosis. 2017;263:e235.
    PubMed     Text format    


  143. CASULA M, Chiodo L, Garlaschelli K, Galimberti F, et al
    Characterization of Italian patients with familial hypercholesterolemia: The lipigen study.
    Atherosclerosis. 2017;263:e235.
    PubMed     Text format    


  144. SCHWARZOVA L, Horinek A, Hubacek J, Zlatohlavek L, et al
    Mutation analysis of the LDLR gene in Czech hypercholesterolemic patients.
    Atherosclerosis. 2017;263:e234.
    PubMed     Text format    


  145. KAYA E, Kayikcioglu M, Payzin S, Can LH, et al
    Aortic elastic properties of familial hypercholesterolemia patients.
    Atherosclerosis. 2017;263:e234-e235.
    PubMed     Text format    


  146. LATKOVSKIS G, Saripo V, Gilis D, Upena-Roze A, et al
    The first results of the Latvian registry of familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e233.
    PubMed     Text format    


  147. VOHNOUT B, Fabryova L, Klabnik A, Kadurova M, et al
    Treatment pattern of familial hypercholesterolemia in slovakia: Targets, treatment and obstacles in common practice.
    Atherosclerosis. 2017;263:e233.
    PubMed     Text format    


  148. SCHMIDT N, Dressel A, Marz W
    First data from the German cascade screening program for familial hypercholesterolemia - care high.
    Atherosclerosis. 2017;263:e233-e234.
    PubMed     Text format    


  149. COCCI G, Cenci A, Bordicchia M, Sarzani R, et al
    LDLR, PCSK9, and LDLRAP1 mutations in the same patient in a familial hypercholesterolemia (FH) family.
    Atherosclerosis. 2017;263:e232.
    PubMed     Text format    


  150. ARNESEN KE, Mork I, Thorwall M, Retterstol K, et al
    Treat-to-target familial hypercholesterolemia (TTT-FH)-a prospective study of high-intensity lipid treatment in free living patients with familial hypercholesterolemia (FH).
    Atherosclerosis. 2017;263:e232-e233.
    PubMed     Text format    


  151. COHEN H, Pinhas-Hamie O, Harats D, Bitzur R, et al
    Carotid imt and plasma lipid levels among children and adolescents with familial hypercholesterolemia. A single center experience 2007-2014.
    Atherosclerosis. 2017;263:e232.
    PubMed     Text format    


  152. SEMENOVA A, Sergienko I, Ezhov M, Garcia-Giustiniani D, et al
    The presence of pathogenic mutations in patients with definite or probable diagnosis of familial hypercholesterolemia defined by targeted next generation sequencing.
    Atherosclerosis. 2017;263:e231.
    PubMed     Text format    


  153. LIN J, Wu X
    Cascade screening, clinical features and genetic aspects-familial hypercholesterolemia study in China.
    Atherosclerosis. 2017;263:e231.
    PubMed     Text format    


  154. SOLOVIEVA E, Ezhov M, Shakhnovich R, Titov V, et al
    Frequency of familial hypercholesterolemia in patients with premature acute coronary syndrome.
    Atherosclerosis. 2017;263:e230-e231.
    PubMed     Text format    


  155. TOMLINSON B, Hu M, Chan J, Mcintyre A, et al
    Severe familial hypercholesterolaemia in two brothers with three heterozygous coding mutations in LDLR.
    Atherosclerosis. 2017;263:e230.
    PubMed     Text format    


  156. TOMLINSON B, Hu M, Chan J, Mcintyre A, et al
    Severe hypertriglycerideamia related to a novel mutation in TRIB1 and a known variant in APOA5.
    Atherosclerosis. 2017;263:e230.
    PubMed     Text format    


  157. ALARCON GARCIA JC, Gonzalez Estrada A, Camacho Carrasco A, Garcia Ocana P, et al
    Combination therapy of Evolocumab and LDL apheresis in patients with heterozygous familial hypercholesterolemia: A case series.
    Atherosclerosis. 2017;263:e230.
    PubMed     Text format    


  158. REKALDE LS, Kovtsun J, Gorzelak-Pabis P, Zuszek-Frynas A, et al
    The incidence of familiar hypercholesterolemia in patients of the cardiology and internal diseases department in a Lodz hospital and their treatment analysis.
    Atherosclerosis. 2017;263:e228-e229.
    PubMed     Text format    


  159. ALVES AC, Medeiros AM, Padeira G, Ferreira AC, et al
    Sitosterolaemia: A case of rare hypercholesterolaemia in Fh patient's cohort.
    Atherosclerosis. 2017;263:e228.
    PubMed     Text format    


  160. PANG J, Abraham A, Bates TR, Bell DA, et al
    Predictors of subclinical coronary artery disease in asymptomatic patients with familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e228.
    PubMed     Text format    


  161. POJSKIC B, Stimjanin E, Pojskic L, Selimovic H, et al
    Connection between foreign body in the eye and familial hypercholesterolemia -case report.
    Atherosclerosis. 2017;263:e228.
    PubMed     Text format    


  162. SHAKHTSHNEIDER E, Orlov P, Ivanoshchuk D, Makarenkova K, et al
    Analysis of the LDLR gene variability in patients with familial hypercholesterolemia in Russia using targeted high throughput resequencing.
    Atherosclerosis. 2017;263:e227.
    PubMed     Text format    


  163. BATURINA O, Mironova O
    Clinical case of hyperlipidemia type IV in a man with diabetes, myocardial infarction and stroke.
    Atherosclerosis. 2017;263:e227-e228.
    PubMed     Text format    


  164. GRITZMACHER L, Bayly G, Honeychurch J, Williams M, et al
    The critical role of segregation analysis in determining the pathogenicity of variants of uncertain significance in patients with suspected familial hypercholesterolaemia.
    Atherosclerosis. 2017;263:e226.
    PubMed     Text format    


  165. HUBACEK JA, Adamkova V, Lanska V, Dlouha D, et al
    Polygenous hypercholesterolemia. Replication of GWAS results on Czech slavonic population.
    Atherosclerosis. 2017;263:e226-e227.
    PubMed     Text format    


  166. HUBACEK JA, Adamkova V, Vrablik M, Ceska R, et al
    Common polymorphisms as strong predictors of hypertriglyceridemia in Czech population.
    Atherosclerosis. 2017;263:e226.
    PubMed     Text format    


  167. URAZGILDEEVA S, Muzalevskaya M, Tregubov A, Nekrasova T, et al
    Main cardiovascular risk factors and HDL rather than LDL and LP(a) levels predict premature atherosclerotic cardiovascular disease in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e226.
    PubMed     Text format    


  168. MOLLAKI V, Drogari E
    Molecular findings of monogenic familial hypercholesterolemia in the Greek population.
    Atherosclerosis. 2017;263:e225.
    PubMed     Text format    


  169. KYSELAK O, Freiberger T, Kovar J, Tichy L, et al
    Atypical phenotype of homozygous familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e224.
    PubMed     Text format    


  170. ILIC GG
    LDL cholesterol and familial hypercholesterolemia in children. Significance of familial history in detecting familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e224.
    PubMed     Text format    


  171. KHOKHLOV R, Tribuntseva L, Burlachuk V, Khokhlov L, et al
    Search strategy of familial hypercholesterolemia among hospitalized patients.
    Atherosclerosis. 2017;263:e224.
    PubMed     Text format    


  172. CHORA JR, Alves AC, Medeiros AM, Bourbon M, et al
    Systematic review of LDLR mutations associated to familial hypercholesterolaemia - evidence of functional studies and application of acmg guidelines for FH diagnosis.
    Atherosclerosis. 2017;263:e221.
    PubMed     Text format    


  173. OGURA M, Morimoto M, Harada-Shiba M
    Antioxidant property of HDL as well as cholesterol efflux capacity are independent risk markers for atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e218.
    PubMed     Text format    


  174. DACLAT R, Bittar R, Salem JE, Ricaldi S, et al
    Postprandial apolipoprotein B-48 level is independent of insulin secretion in patients with moderate or severe hypertriglyceridemia.
    Atherosclerosis. 2017;263:e211.
    PubMed     Text format    


  175. OYRI LKL, Hansson P, Bogsrud MP, Narverud I, et al
    Postprandial response after intake of saturated fat compared to polyunsaturated fat in subjects with familial hypercholesterolemia and normolipidemic controls-a randomized controlled trial.
    Atherosclerosis. 2017;263:e210.
    PubMed     Text format    


  176. GRIVA E, Kyrkou K, Stamatelopoulos K, Drogari E, et al
    The effect of Lp(a) on cardiovascular function in greek pediatric population 6-16 years old. Preliminary findings in children with or without familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e207-e208.
    PubMed     Text format    


  177. SEED M, Sharifi M, Nair D, Jain A, et al
    Lipoprotein(a) level is higher inpatients with familial hypercholesterolaemia than in normal healthy subjects, contribution of variants in the LPA gene.
    Atherosclerosis. 2017;263:e207.
    PubMed     Text format    


  178. POLYPATHELLI I, Demosthenous C, Gavra M, Matsaridou E, et al
    Hypertriglyceridemia-induced acute pancreatitis in third trimester of pregnancy: A case report.
    Atherosclerosis. 2017;263:e203-e204.
    PubMed     Text format    


  179. BENIMETSKAYA K, Ragino Y, Shakhtshneider E, Makarenkova K, et al
    Proprotein convertase subtilisin/kexin type 9 (PCSK9) level in patients with familial hypercholesterolemia in Russia.
    Atherosclerosis. 2017;263:e195.
    PubMed     Text format    


  180. ERSHOVA A, Meshkov A, Bazhan S, Storozhok M, et al
    The prevalence of heterozygous familial hypercholesterolemia in the Russian Federation: A substudy of the ESSE-Rf.
    Atherosclerosis. 2017;263:e184-e185.
    PubMed     Text format    


  181. FARES AL, Hussein El Bacha AA, Souza CS, Garcia De Carvalho JA, et al
    High prevalence of familial hypercholesterolemia in patients with coronary heart disease at a Brazilian quaternary healthcare center.
    Atherosclerosis. 2017;263:e181-e183.
    PubMed     Text format    


  182. SCICALI R, Platania R, Purrazzo G, Giannone A, et al
    Screening for unknown hypercholesterolemia in a hospital population: A model for preventive medicine.
    Atherosclerosis. 2017;263:e181.
    PubMed     Text format    


  183. ALVES R, Yamaya A, Souza A, Rosa R, et al
    Identification of patients with familial hypercholesterolemia in dyslipidemia ambulatory of public hospital.
    Atherosclerosis. 2017;263:e179.
    PubMed     Text format    


  184. IYENGAR S, Gupta R, Ravi S
    Looking for a needle in a haystack? Familial hypercholesterolemia in coronary artery disease.
    Atherosclerosis. 2017;263:e177.
    PubMed     Text format    


  185. DUMITRESCU A, Mosteoru S, Gaita D, Mut G, et al
    The prevalence of familial hypercholesterolemia in children from Timisoara.
    Atherosclerosis. 2017;263:e170-e171.
    PubMed     Text format    


  186. SANZ AMB, Jarauta E, Perez-Calahorra S, Marco-Benedi V, et al
    Association between carotid plaque and coronary events in subjects with genetic hypercholesterolemia.
    Atherosclerosis. 2017;263:e17-e18.
    PubMed     Text format    


  187. GOCMEN AY, Gumuslu S
    Atorvastatin influences oxidative stress markers in hypercholesterolemic rats.
    Atherosclerosis. 2017;263:e162.
    PubMed     Text format    


  188. ALYAHYA AM, Al Masri A, Eleter E, Alhersi A, et al
    Progranulin attenuates in vivo acute myocardial ischemia/reperfusion injury in a rat model of hypercholesterolemia.
    Atherosclerosis. 2017;263:e148-e149.
    PubMed     Text format    


  189. FUSTER JJ, Maclauchlan S, Zuriaga MA, Polackal MN, et al
    Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis in hyperlipidemic mice.
    Atherosclerosis. 2017;263:e14.
    PubMed     Text format    


  190. KRITIKOU E, Van Der Heijden T, Maarten S, Van Duijn J, et al
    Hypercholesterolemia induces a mast cell-CD4+ T-cell interaction in atherosclerosis.
    Atherosclerosis. 2017;263:e124.
    PubMed     Text format    


  191. MOREGOLA A, Bonacina F, Coe D, Pellegatta F, et al
    LDLR influence on CD4 T cells differentiation in mice and in familial hypercholesterolemia patients.
    Atherosclerosis. 2017;263:e115.
    PubMed     Text format    


  192. MACCHI C, Botta M, Bosisio R, Pavanello C, et al
    Efficacy and safety of a nutraceutical with probiotic and red yeast rice extract in patients with moderate hypercholesterolemia: A randomized, double-blind, placebo-controlled study.
    Atherosclerosis. 2017;263:e109.
    PubMed     Text format    


  193. OGURA M, Furuhashi M, Morimoto M, Matsumoto M, et al
    Fatty acid-binding protein 5 as a residual risk for atherosclerotic cardiovascular disease in patients with familial hypercholesterolemia.
    Atherosclerosis. 2017;263:e100.
    PubMed     Text format    


    July 2017
  194. NIKKOLA E, Ko A, Alvarez M, Cantor RM, et al
    Family-specific aggregation of lipid GWAS variants confers the susceptibility to familial hypercholesterolemia in a large Austrian family.
    Atherosclerosis. 2017;264:58-66.
    PubMed     Text format     Abstract available


  195. YANG ZH, Gordon SM, Sviridov D, Wang S, et al
    Dietary supplementation with long-chain monounsaturated fatty acid isomers decreases atherosclerosis and alters lipoprotein proteomes in LDLr(-/-) mice.
    Atherosclerosis. 2017;262:31-38.
    PubMed     Text format     Abstract available


  196. STEINHAGEN-THIESSEN E, Stroes E, Soran H, Johnson C, et al
    The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.
    Atherosclerosis. 2017;262:146-153.
    PubMed     Text format     Abstract available


    June 2017
  197. SUDO M, Li Y, Hiro T, Takayama T, et al
    Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits.
    Atherosclerosis. 2017 Jun 23. pii: S0021-9150(17)31169.
    PubMed     Text format     Abstract available


  198. SILVA PRS, Jannes CE, Oliveira TGM, Miname MH, et al
    Evaluation of clinical and laboratory parameters used in the identification of index cases for genetic screening of familial hypercholesterolemia in Brazil.
    Atherosclerosis. 2017;263:257-262.
    PubMed     Text format     Abstract available


  199. BERBEE JFP, Mol IM, Milne GL, Pollock E, et al
    Deuterium-reinforced polyunsaturated fatty acids protect against atherosclerosis by lowering lipid peroxidation and hypercholesterolemia.
    Atherosclerosis. 2017 Jun 21. pii: S0021-9150(17)31165.
    PubMed     Text format     Abstract available


  200. SANTOS RD, Miname MH
    Increased subclinical atherosclerosis burden in familial hypercholesterolemia phenotype: What do genetic defects tell us and what are the clinical implications?
    Atherosclerosis. 2017 Jun 12. pii: S0021-9150(17)30254.
    PubMed     Text format    


  201. VONGPROMEK R, Bos S, Ten Kate GR, Bujo H, et al
    Soluble LR11 associates with aortic root calcification in asymptomatic treated male patients with familial hypercholesterolemia.
    Atherosclerosis. 2017 Jun 9. pii: S0021-9150(17)30268.
    PubMed     Text format     Abstract available


  202. BEA AM, Perez-Calahorra S, Marco-Benedi V, Lamiquiz-Moneo I, et al
    Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
    Atherosclerosis. 2017;263:92-96.
    PubMed     Text format     Abstract available


  203. TERAMOTO T, Daida H, Ikewaki K, Arai H, et al
    Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Atherosclerosis. 2017;261:69-77.
    PubMed     Text format     Abstract available


  204. WELTEN SMJ, de Jong RCM, Wezel A, de Vries MR, et al
    Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis.
    Atherosclerosis. 2017;261:26-36.
    PubMed     Text format     Abstract available


  205. ARAI H, Yamashita S, Yokote K, Araki E, et al
    Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipida
    Atherosclerosis. 2017;261:144-152.
    PubMed     Text format     Abstract available


  206. OUWENEEL AB, van der Sluis RJ, Nahon JE, Van Eck M, et al
    Simvastatin treatment aggravates the glucocorticoid insufficiency associated with hypocholesterolemia in mice.
    Atherosclerosis. 2017;261:99-104.
    PubMed     Text format     Abstract available


    May 2017
  207. HAGENSEN MK, Mortensen MB, Kjolby M, Stillits NL, et al
    Type 1 diabetes increases retention of low-density lipoprotein in the atherosclerosis-prone area of the murine aorta.
    Atherosclerosis. 2017;263:7-14.
    PubMed     Text format     Abstract available


  208. SHARIFI M, Higginson E, Bos S, Gallivan A, et al
    Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
    Atherosclerosis. 2017 May 13. pii: S0021-9150(17)30218.
    PubMed     Text format     Abstract available


  209. MASANA L, Plana N, Perez-Calahorra S, Ibarretxe D, et al
    How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Atherosclerosis. 2017;262:107-112.
    PubMed     Text format     Abstract available


  210. BUONUOMO PS, Iughetti L, Pisciotta L, Rabacchi C, et al
    Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia.
    Atherosclerosis. 2017;262:71-77.
    PubMed     Text format     Abstract available


  211. OTHMAN RA, Myrie SB, Mymin D, Roullet JB, et al
    Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia.
    Atherosclerosis. 2017;260:27-33.
    PubMed     Text format     Abstract available


    April 2017
  212. MANGILI LC, Miname MH, Silva PRS, Bittencourt MS, et al
    Achilles tendon xanthomas are associated with the presence and burden of subclinical coronary atherosclerosis in heterozygous familial hypercholesterolemia: A pilot study.
    Atherosclerosis. 2017 Apr 30. pii: S0021-9150(17)30189.
    PubMed     Text format     Abstract available


  213. BOURBON M, Alves AC, Alonso R, Mata N, et al
    Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry.
    Atherosclerosis. 2017;262:8-13.
    PubMed     Text format     Abstract available


    March 2017
  214. LI S, Wu NQ, Zhu CG, Zhang Y, et al
    Significance of lipoprotein(a) levels in familial hypercholesterolemia and coronary artery disease.
    Atherosclerosis. 2017;260:67-74.
    PubMed     Text format     Abstract available


  215. FUTEMA M, Cooper JA, Charakida M, Boustred C, et al
    Screening for familial hypercholesterolaemia in childhood: Avon Longitudinal Study of Parents and Children (ALSPAC).
    Atherosclerosis. 2017;260:47-55.
    PubMed     Text format     Abstract available


    February 2017
  216. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Atherosclerosis. 2017;259:20-25.
    PubMed     Text format     Abstract available


  217. JANUS ED
    Homozygous familial hypercholesterolaemia - Early recognition and early treatment improve outcomes.
    Atherosclerosis. 2017 Feb 16. pii: S0021-9150(17)30060.
    PubMed     Text format    


  218. XIANG R, Fan LL, Lin MJ, Li JJ, et al
    The genetic spectrum of familial hypercholesterolemia in the central south region of China.
    Atherosclerosis. 2017;258:84-88.
    PubMed     Text format     Abstract available


  219. LADWIG KH, Baumert J, Marten-Mittag B, Lukaschek K, et al
    Room for depressed and exhausted mood as a risk predictor for all-cause and cardiovascular mortality beyond the contribution of the classical somatic risk factors in men.
    Atherosclerosis. 2017;257:224-231.
    PubMed     Text format     Abstract available


    January 2017
  220. WIDHALM K, Benke IM, Fritz M, Geiger H, et al
    Homozygous familial hypercholesterolemia: Summarized case reports.
    Atherosclerosis. 2017;257:86-89.
    PubMed     Text format     Abstract available


  221. BRUCKERT E, Kalmykova O, Bittar R, Carreau V, et al
    Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Atherosclerosis. 2017;257:130-137.
    PubMed     Text format     Abstract available


  222. BOS S, Duvekot MH, Ten Kate GR, Verhoeven AJ, et al
    Carotid artery plaques and intima medial thickness in familial hypercholesteraemic patients on long-term statin therapy: A case control study.
    Atherosclerosis. 2017;256:62-66.
    PubMed     Text format     Abstract available


    December 2016
  223. DURST R, Ibe UK, Shpitzen S, Schurr D, et al
    Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Atherosclerosis. 2016;257:55-63.
    PubMed     Text format     Abstract available


  224. PANES O, Gonzalez C, Hidalgo P, Valderas JP, et al
    Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
    Atherosclerosis. 2016;257:164-171.
    PubMed     Text format     Abstract available


  225. CHRISTENSEN JJ, Osnes LT, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;256:67-74.
    PubMed     Text format     Abstract available


  226. BOOT C, Holmes E, Neely RD
    Serum non-HDL cholesterol to apolipoprotein B ratio as a screening test for familial dysbetalipoproteinaemia (Type III hyperlipidaemia) in patients with mixed hyperlipidaemia.
    Atherosclerosis. 2016;255:7.
    PubMed     Text format    


  227. HARALAMBOS K, Ashfield-Watt P, Edwards R, Gingell R, et al
    Five year experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in wales: Should the criteria be refined to include age?
    Atherosclerosis. 2016;255:7-8.
    PubMed     Text format    


  228. HONEYCHURCH J, Watson E, Hills A, Dean P, et al
    Validation and utility of a new NGS assay for familial hypercholesterolaemia incorporating 12 LDL-C-raising SNPs.
    Atherosclerosis. 2016;255:6-7.
    PubMed     Text format    


  229. GOYALE A, Jain A, Sharifi M, Gallivan A, et al
    Validation of low density lipoprotein correction factors in a multi-ethnic familial hypercholesterolaemia population at a North London lipid clinic.
    Atherosclerosis. 2016;255:6.
    PubMed     Text format    


  230. SHARIFI M, Jain A, Persaud J, Humphries SE, et al
    Cardiovascular biomarkers in monogenic familial hypercholesterolaemia and polygenic hypercholesterolaemia.
    Atherosclerosis. 2016;255:4.
    PubMed     Text format    


  231. HILLS A, Honeychurch J, Davies J, Robinson C, et al
    4 years' cascade genetic testing for familial hypercholesterolaemia in England - Increased referrals and ascertainment.
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  232. KATE HARALAMBOS K, Whitmore J
    Using pass database and geographic information systems (GIS) to map familial hypercholesterolaemia (FH) diagnoses in England and Wales.
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  233. LUNGLEY J, Jayne Z, Harvey D, Nair DR, et al
    Early identification of familial hypercholesterolaemIa (FH): The prevention of Cardiovascular disease (CVD).
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  234. GRITZMACHER L, Bayly GR, Williams M, Hills A, et al
    The critical importance of segregation analysis in the management of patients and their families with suspected familial hypercholesterolaemia: 3 examples from the bristol FH clinic.
    Atherosclerosis. 2016;255:2-3.
    PubMed     Text format    


  235. COZENS A, McMahon S, Purves J, Miedzybrodska Z, et al
    Detection, assessment and treatment of children with familial hypercholesterolaemia in Scotland.
    Atherosclerosis. 2016;255:2.
    PubMed     Text format    


  236. GELLATLY E
    Familial hypercholesterolaemia (FH) - Finding the needle in a haystack in a Scottish population.
    Atherosclerosis. 2016;255:2.
    PubMed     Text format    


  237. ASHFIELD-WATT P, Haralambos K, Edwards R, Townsend D, et al
    Estimation of the prevalence of cholesteryl ester storage disorder (CESD) in a cohort of patients with clinical features of familial hypercholesterolaemia.
    Atherosclerosis. 2016;255:1.
    PubMed     Text format    


    November 2016
  238. FRANCE M, Rees A, Datta D, Thompson G, et al
    HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    Atherosclerosis. 2016 Nov 5. pii: S0021-9150(16)31420.
    PubMed     Text format     Abstract available


    October 2016
  239. SETIA N, Saxena R, Arora A, Verma IC, et al
    Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.
    Atherosclerosis. 2016;255:31-36.
    PubMed     Text format     Abstract available


  240. DANCER M, Caussy C, Di Filippo M, Moulin P, et al
    Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3'UTR variant SstI.
    Atherosclerosis. 2016;255:6-10.
    PubMed     Text format     Abstract available


  241. CASULA M, Scotti L, Tragni E, Merlino L, et al
    Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016;254:172-178.
    PubMed     Text format     Abstract available


  242. OGURA M, Makino H, Kamiya C, Yoshimatsu J, et al
    Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
    Atherosclerosis. 2016;254:179-183.
    PubMed     Text format     Abstract available


    September 2016
  243. KOSTNER K
    Coronary calcification in familial hypercholesterolemia: Not all about LDL.
    Atherosclerosis. 2016 Sep 28. pii: S0021-9150(16)31377.
    PubMed     Text format    


  244. MARTIN R, Latten M, Hart P, Murray H, et al
    Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Atherosclerosis. 2016;254:8-13.
    PubMed     Text format     Abstract available


  245. MANGILI LC, Mangili OC, Bittencourt MS, Miname MH, et al
    Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia.
    Atherosclerosis. 2016;254:73-77.
    PubMed     Text format     Abstract available


  246. ARCA M
    Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Atherosclerosis. 2016 Sep 2. pii: S0021-9150(16)31315.
    PubMed     Text format     Abstract available


    May 2016
  247. NARDIN M, Verdoia M, Schaffer A, Barbieri L, et al
    Vitamin D status, diabetes mellitus and coronary artery disease in patients undergoing coronary angiography.
    Atherosclerosis. 2016;250:114-121.
    PubMed     Text format     Abstract available


  248. BANERJEE Y, Santos RD, Al-Rasadi K, Rizzo M, et al
    Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Atherosclerosis. 2016;248:62-75.
    PubMed     Text format     Abstract available


    March 2016
  249. CAUSSY C, Charriere S, Meirhaeghe A, Dallongeville J, et al
    Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
    Atherosclerosis. 2016;246:280-6.
    PubMed     Text format     Abstract available


  250. POKHAREL Y, Steinberg L, Chan W, Akeroyd JM, et al
    Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Atherosclerosis. 2016;246:115-20.
    PubMed     Text format     Abstract available


  251. SCHWEITZER M, Makhoul S, Paliouras M, Beitel LK, et al
    Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Atherosclerosis. 2016;246:78-86.
    PubMed     Text format     Abstract available


    January 2016
  252. ZHENG L, Wu T, Zeng C, Li X, et al
    SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.
    Atherosclerosis. 2016;244:179-87.
    PubMed     Text format     Abstract available


  253. FARNIER M, Jones P, Severance R, Averna M, et al
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Atherosclerosis. 2016;244:138-46.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: